Premium
Liver fibrosis attributed to lipid lowering medications: two cases
Author(s) -
Punthakee Z.,
Scully L. J.,
Guindi M. M.,
Ooi T. C.
Publication year - 2001
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1046/j.1365-2796.2001.00848.x
Subject(s) - medicine , fibrate , fibrosis , liver fibrosis , chronic hepatitis , gastroenterology , statin , hepatitis , liver damage , immunology , virus
. Punthakee Z, Scully LJ, Guindi MM, Ooi TC (Department of Medicine, Division of Gastroenterology, Department of Pathology and the Laboratory of Medicine and the Division of Endocrinology and Metabolism, The Ottawa Hospital – Civic Campus, University of Ottawa, Ottawa, Canada). Liver fibrosis attributed to lipid lowering medications: two cases (Case Report). J Intern Med 2001; 250: 249–254. We identified two cases of chronic active hepatitis with liver fibrosis induced by lipid lowering drugs of the statin and fibrate classes despite regular monitoring of transaminases. There are few reports of clinically significant hepatitis induced by these drugs and even fewer cases of fibrosis. Given the growing use of these drugs, there are implications for monitoring patients on long‐term therapy for liver damage.